News Annexin Pharmaceuticals AB

Equities

ANNX

SE0009664154

Market Closed - Nasdaq Stockholm Other stock markets 08:24:42 26/04/2024 pm IST			5-day change	1st Jan Change
0.297 ^SEK	+2.41%		+10.00%	+14.23%

12/04	Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
09/02	Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Last patient treated in Annexin’s RVO study - promising signals of effect and no safety concerns	25/04	AQ
BioStock: Annexin towards completion of phase II study and share issue	18/04	AQ
Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024	12/04	CI
Annexin resolves on a rights issue of SEK 45.1 million guaranteed to 90 percent, subject to approval by the 2024 Annual General Meeting, which has been decided to be brought forward	28/03	AQ
BioStock: Strong start for Annexin in 2024	14/02	AQ
Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	09/02	CI
Update on Annexin´s RVO study confirms promising signals of effect	08/02	AQ
Annexin Pharmaceuticals AB Provides Update on RVO Study Confirms Promising Signals of Effect	08/02	CI
Annexin presents at Redeye’s Fight Cancer event on January 24	18/01	AQ
Annexin announces outcome of the rights issue and resolves on directed issues to guarantors and lenders	19/12	AQ
The subscription period in Annexin Pharmaceuticals’ rights issue begins today	30/11	AQ
Annexin Pharmaceuticals publishes prospectus in connection with forthcoming rights issue	28/11	AQ
First patients treated with higher dose without adverse events in Annexin's RVO study	23/11	AQ
Annexin granted additional patent protection in the US	14/11	AQ
Annexin Pharmaceuticals AB Announces Additional Patent Protection in the US	14/11	CI
First patient treated in the second dose group in Annexin's RVO study	25/23/25	PR
First patient treated in the second dose group in Annexin's RVO study	25/23/25	AQ
Annexin Pharmaceuticals AB Announces First Patient Treated in the Second Dose Group in RVO Study	25/23/25	CI
Annexin resolves a SEK 35.6 million fully guaranteed rights issue, subject to approval of an Extraordinary General Meeting	24/23/24	AQ
BioStock: Annexin's CSO on progress in cancer initiative	18/23/18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Annexin Pharmaceuticals AB

Equities

ANNX

SE0009664154

Summary

Filters